Kamada (NASDAQ:KMDA) Downgraded by StockNews.com to “Buy”

StockNews.com lowered shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning.

Several other equities analysts have also issued reports on KMDA. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th. Benchmark initiated coverage on Kamada in a research report on Friday, March 21st. They issued a “buy” rating and a $15.00 target price on the stock.

Kamada Trading Down 0.3 %

NASDAQ KMDA opened at $7.08 on Tuesday. The firm’s 50 day simple moving average is $7.19 and its 200 day simple moving average is $6.28. The firm has a market capitalization of $406.96 million, a price-to-earnings ratio of 25.29, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16.

Kamada Dividend Announcement

The company also recently declared a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Institutional Investors Weigh In On Kamada

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in Kamada in the fourth quarter valued at about $67,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada in the third quarter valued at approximately $77,000. NewEdge Advisors LLC increased its stake in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the period. Geode Capital Management LLC raised its holdings in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC boosted its position in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the period. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.